TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A randomized trial of 61 healthy adults found that participants assigned a daily multi-ingredient supplement had improved measures of endothelial function, arterial stiffness and systolic blood pressure after six months. Only 43 participants completed both visits, and the study measured vascular markers—not heart attacks, strokes or other cardiovascular events.
A six-month randomized trial found that healthy adults taking a daily supplement combining vitamins, minerals, amino acids and plant-derived compounds had improved endothelial function, lower arterial stiffness and a reduction in systolic blood pressure. The findings, published in European Heart Journal Open, point to possible changes in vascular health markers, but the small study did not test whether the supplement prevents heart attacks or strokes.
Researchers at the University of Surrey enrolled 61 healthy adults and assigned them to receive either the active nutritional powder or a similar-looking powder without active ingredients. Participants took their assigned product daily for six months. The primary analysis included 43 people who completed both study visits, fewer than the total initially randomized.
The team assessed vascular measures at the start and end of the study, and also measured some responses one hour after the first dose. Endothelial function improved in the supplement group over six months and changed little in the control group. It also improved in the active group after the first dose, though that short-term response does not establish a lasting benefit on its own.
The supplement group had a significant reduction in arterial stiffness and systolic blood pressure at six months; the control group’s arterial stiffness increased, while its blood-pressure reduction was smaller. Diastolic blood pressure did not differ significantly between groups after the intervention. Cholesterol measures—including total cholesterol, LDL, HDL and triglycerides—were comparable between groups. The estimated 10-year risk of a first atherosclerotic cardiovascular event shifted slightly in opposite directions, but the researchers said the difference was driven mainly by systolic blood pressure. The trial did not record actual cardiovascular events.
What the Vascular Measures Show
The results matter because blood-vessel function, arterial stiffness and blood pressure are linked to cardiovascular health and tend to change with age. A product that affects several of these measures could merit further study, particularly since the intervention combined compounds intended to act on different biological pathways.
But changes in these markers are not the same as evidence that a supplement prevents cardiovascular disease. The study was small, lasted six months and included healthy adults; it cannot establish whether any observed changes persist or translate into fewer heart attacks, strokes or deaths. The findings also do not show that every ingredient contributed, or that the combination works better than its components would individually.
For readers, the central takeaway is a promising early signal, not a proven preventive treatment. The trial does not establish that people should start taking the product, and it does not replace established approaches to cardiovascular risk management. Anyone considering a supplement for a health condition or alongside medication should discuss it with a qualified health professional.
Products Worth Considering
Withings BPM Connect Blood Pressure Monitor with Wi-Fi and Bluetooth
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Blueair Blue Pure 311i Max Smart Air Purifier
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested a Combination
Vascular aging involves gradual changes in blood vessels, including reduced endothelial function, greater arterial stiffness and higher blood pressure. The study report describes several processes that may contribute, such as oxidative stress, low-grade inflammation, mitochondrial dysfunction and changes in nitric oxide availability.
Research has examined plant compounds, amino acids and micronutrients individually, but the report says evidence for multi-compound interventions in people remains limited. The Surrey trial was designed to address that gap by testing a combination of ingredients at once. Because the intervention bundled multiple compounds, the study does not identify which ingredients, if any, were responsible for the measured effects.
“The supplement was designed to target complementary pathways relevant to vascular aging.”
— The study authors, as summarized in the News-Medical report
What the Trial Cannot Establish
The report does not provide enough detail to judge how broadly the findings apply, including the participants’ age range, the supplement’s full ingredient amounts, or the reasons 18 of the 61 randomized participants were not included in the primary analysis. It also does not specify whether the observed changes were large enough to be clinically meaningful.
It remains unknown whether the marker changes would persist beyond six months, occur in older adults or people with cardiovascular conditions, or affect real-world rates of disease. Since the study tested a mixture, it cannot establish the effects of each ingredient separately. The reported 10-year risk estimate is a calculation based on risk factors, not evidence that the supplement changed participants’ actual long-term outcomes.
Evidence Needed Beyond Six Months
The study report says the findings need confirmation in larger and longer clinical trials. Further research would need to recruit more participants, clarify who benefits and assess whether changes in vascular measures persist. Trials designed to track clinical outcomes would be needed to determine whether supplementation affects cardiovascular events, rather than only intermediate markers.
Until such evidence is available, the present results are best treated as an early research finding. The report does not announce a next trial, a regulatory decision or a change to clinical guidance, so the timing and design of further studies remain unclear.
Key Questions
What did the supplement trial find?
Among participants included in the primary analysis, the supplement group showed improved endothelial function, reduced arterial stiffness and lower systolic blood pressure after six months compared with the control group’s pattern. The study did not find a significant between-group difference in diastolic blood pressure or cholesterol measures.
Did the supplement prevent heart attacks or strokes?
No. The trial did not assess actual cardiovascular events. It reported changes in vascular measures and a calculated 10-year risk estimate, which is not the same as observing whether participants had heart attacks or strokes.
How many people took part?
Sixty-one healthy adults were randomized, but 43 completed both study visits and were included in the primary analysis. The report does not give the reasons for the difference.
Does the study show that people should take this supplement?
No. A small, six-month trial cannot establish that the supplement prevents disease or is appropriate for everyone. People considering supplements, especially alongside medicines or for a health condition, should consult a qualified health professional.
Source: news-medical.net
